Conference abstract · 26 Oct 2015
Conference abstractPublished 26 Oct 2015
ERBITUX BIOSIMILAR
USC Keck School of Medicine, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Supported by a NCI SBIR contract, a biosimilar Erbitux antibody, designated ch225, has been developed over the last three years for the immunotherapy of EGFR+, KRAS mutation negative tumors. In 2011, there were 141,210 new cases of colon and rectal cancers and 49,380 deaths in the USA accounting for the 12.2 billion dollars spent on colorectal cancer treatment alone. In addition,head and neck cancers account for 45,000 additional cases that are eligible for Erbitux treatment. These statistics show that Erbitux is an important treatment modality especially since its therapeutic effects against other tumors such as non-small cell lung cancer has been demonstrated.After extensive analyses of commercial Erbitux, a biosimilar antibodywas developed using genetic engineering methods. Our initial studies demonstratedthat ch225 has the same primary amino acid sequence, charge distribution, and glycosylation profile as Erbitux required for its biosimilarity. In addition, the potencyof ch225 against EGFR positive and negative cell linesand PK/PD studies closely matched commercial Erbitux batches both in vitro and in vivo. Based upon these results, extensive cloning methods were used to develop a high yielding subclonein serum free medium which produces over 1mg/ml of antibody stable out to 35 generations. A growth supplement was also identified which increased its productivity enabling the accumulation of 4 x 107 cells/ml with over 98% viability. In conclusion, despite numerous difficulties encountered during the course of this work, a biosimilar Erbitux has been produced and readied for cGMP and clinical trials.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Article · 27 Feb 2026
Emerging Trends in Biosimilars and Biopharmaceuticals
Article · 30 Oct 2025
Biosimilars as a Sustainable Pathway for Advancing Modern Therapeutics
Article · 30 Oct 2025
The Evolving Role of Biosimilars in Enhancing Global Healthcare Access
Opinion · 29 Sep 2025
Biosimilars: Affordable Access, Enhanced Healthcare in Developing Nations
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- BylineArticles whose byline prints “Alan L. Epstein”
